Sage Therapeutics to Host Sage FutureCast Webcast
November 29 2021 - 5:30AM
Business Wire
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical
company committed to developing novel therapies with the potential
to transform the lives of people with debilitating disorders of the
brain, today announced that it will host Sage FutureCast: An
R&D and Portfolio Review on Tuesday, December 14 from 8:00 a.m.
to 10:00 a.m. ET.
Sage FutureCast will discuss the Company’s research and
development strategy, and clinical progress in programs throughout
the depression, neurology, and neuropsychiatry franchises including
zuranolone, SAGE-324 and SAGE-718, respectively.
Webcast Information A live webcast of the presentation
can be accessed on the investor page of Sage's website at
investor.sagerx.com. A replay of the webcast will be available on
Sage's website approximately two hours after the completion of the
event and will be archived for up to 30 days.
About Sage Therapeutics Sage Therapeutics is a
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with
debilitating disorders of the brain. We are pursuing new pathways
with the goal of improving brain health, and our depression,
neurology and neuropsychiatry franchise programs aim to change how
brain disorders are thought about and treated. Our mission is to
make medicines that matter so people can get better, sooner. For
more information, please visit www.sagerx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211129005132/en/
Investor Contact Helen Rubinstein 315-382-3979
helen.rubinstein@sagerx.com
Media Contact Maureen L. Suda 617-949-4289
maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024